Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2020

View Archived Issues

Epigenetic therapy disrupts premetastatic microenvironment

FDA clears IND application for AIM-001

First patient dosed in phase I study of HLX-55

Nascent Biotech to evaluate the potential of pritumumab as therapy for COVID-19

Phase III data reported from ESCAPE-NA1 study of nerinetide

FGL1 as a novel therapeutic target in obesity

Forma Therapeutics patents HDAC6 inhibitors

Gudui Biopharma Technology identifies new compounds for stroke

Merck & Co. divulges new IDO1 inhibitors

Caloric restriction prevents negative aging effects in rats

Lead Discovery Center synthesizes HER2 and EGFR inhibitors

Target Biopharmaceutical Technology Shenzhen discloses SN-38 derivatives

SMARCA4 expression is lost in sinonasal teratocarcinosarcoma

miR-10a-5p found to be a therapeutic target for treating NSCLC

Bayer initiates phase II study of BAY-2586116 in obstructive sleep apnea

Takeda begins development of anti-SARS-CoV-2 polyclonal H-IG

New phase I trial studies imaging agent I-124 M5A to detect liver metastases from colorectal cancer

Identification of orally available PI3Kdelta inhibitors unveils Vps34 as a key selectivity target

PTP1B has a key role in memory impairment and neurodegeneration in a mouse model of familial AD

ZEB1 is associated with poorer survival in peritoneal malignant mesothelioma

EpiVax collaborates with University of Georgia and Generex to develop COVID-19 vaccines

Genentech opening enrollment in phase I study of XmAb-24306 for advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...